On Monday, Arcutis Biotherapeutics Inc (NASDAQ: ARQT) opened lower -4.69% from the last sessionbefore settling in for the closing price of $10.66. Price fluctuations for ARQT have ranged from $1.76 to $13.17 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 303.42% over the past five years. Company’s average yearly earnings per share was noted 59.98% at the time writing. With a float of $101.40 million, this company’s outstanding shares have now reached $116.89 million.
Let’s look at the performance matrix of the company that is accounted for 296 employees. In terms of profitability, gross margin is 92.17%, operating margin of -136.13%, and the pretax margin is -147.95%.
Arcutis Biotherapeutics Inc (ARQT) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Arcutis Biotherapeutics Inc is 13.25%, while institutional ownership is 99.47%. The most recent insider transaction that took place on Sep 03 ’24, was worth 107,695. In this transaction Director of this company sold 10,000 shares at a rate of $10.77, taking the stock ownership to the 191,944 shares. Before that another transaction happened on Sep 03 ’24, when Company’s Director proposed sale 10,000 for $10.77, making the entire transaction worth $107,695.
Arcutis Biotherapeutics Inc (ARQT) Latest Financial update
If we go through the results of last quarter, which was made public on 6/30/2024, the company posted -0.73 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.86) by 0.13. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.36 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 59.98% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 9.80% during the next five years compared to -48.07% drop over the previous five years of trading.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Trading Performance Indicators
Check out the current performance indicators for Arcutis Biotherapeutics Inc (ARQT). In the past quarter, the stock posted a quick ratio of 8.19. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.99.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.18, a number that is poised to hit -0.41 in the next quarter and is forecasted to reach -1.15 in one year’s time.
Technical Analysis of Arcutis Biotherapeutics Inc (ARQT)
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) saw its 5-day average volume 1.42 million, a negative change from its year-to-date volume of 3.52 million. As of the previous 9 days, the stock’s Stochastic %D was 32.82%. Additionally, its Average True Range was 0.71.
During the past 100 days, Arcutis Biotherapeutics Inc’s (ARQT) raw stochastic average was set at 73.04%, which indicates a significant increase from 10.69% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 43.79% in the past 14 days, which was lower than the 72.79% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.91, while its 200-day Moving Average is $8.07. Nevertheless, the first resistance level for the watch stands at $10.75 in the near term. At $11.35, the stock is likely to face the second major resistance level. The third major resistance level sits at $11.71. If the price goes on to break the first support level at $9.79, it is likely to go to the next support level at $9.43. The third support level lies at $8.83 if the price breaches the second support level.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Key Stats
There are currently 115,764K shares outstanding in the company with a market cap of 1.19 billion. Presently, the company’s annual sales total 59,610 K according to its annual income of -262,140 K. Last quarter, the company’s sales amounted to 30,860 K and its income totaled -52,330 K.
